$SEPN News

HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target

Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target

Septerna Doses First Participants In Phase 1 Trial Of SEP-479 For Hypoparathyroidism

JP Morgan Maintains Overweight on Septerna, Raises Price Target to $38

Truist Securities Maintains Buy on Septerna, Raises Price Target to $35

Septerna Files Shelf Registration For Future Offerings Of Stock, Debt, Warrants, And Units

Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Earnings Breakdown: Septerna Q4

Earnings Summary: Septerna Q4

Septerna Q4 EPS $(0.24) Misses $0.03 Estimate, Sales $24.118M Miss $32.667M Estimate

Does SEP-631’s Phase 1 Proof-of-Mechanism and 2026 Trial Plan Reshape Septerna’s Mast Cell Strategy (SEPN)?

Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $48

Septerna Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $40

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Septerna's SEP-631 Demonstrated Dose-Dependent Inhibition Of Icatibant-Induced Skin Wheal Formation With Complete Inhibition At Doses As Low As 10 Mg Once-Daily; Well-Tolerated Across All Doses With Adverse Events Comparable To Placebo;

Septerna's SEP-631 Demonstrated Dose-Dependent Inhibition Of Icatibant-Induced Skin Wheal Formation With Complete Inhibition At Doses As Low As 10 Mg Once-Daily; Well-Tolerated Across All Doses With Adverse Events Comparable To Placebo;

Septerna to Present at TD Cowen 46th Annual Health Care Conference